Differentially expressed urinary exo-miRs and clinical outcomes in kidney recipients on short-term tacrolimus therapy: a pilot study.
Renata Caroline Costa FreitasRaul Hernandes BortolinFabiana Dalla Vecchia GenvigirVivian BoneziThiago Dominguez Crespo HirataClaudia Rosso FelipeHélio Tedesco Silva-JuniorJosé Osmar Medina de Abreu PestanaÁlvaro CerdaSonia Quateli DoiMario Hiroyuki HirataRosario Dominguez Crespo HirataPublished in: Epigenomics (2020)
Aim: To analyze the expression of urinary exosome-derived miRNAs (exo-miRs) in kidney recipients on tacrolimus-based therapy. Patients & methods: Clinical and drug monitoring data were recorded from 23 kidney recipients. Expression of 93 exo-miRs was measured by quantitative PCR array and mRNA targets were explored. Results: 16 exo-miRs were differentially expressed, including marked upregulation of miR-155-5p, and downregulation of miR-223-3p and miR-1228-3p. Expression of miR-155-5p and miR-223-3p correlated with tacrolimus dose (p < 0.05), miR-223-3p with serum creatinine (p < 0.05), and miR-223-3p and miR-1228-3p with blood leukocytes (p < 0.05). 12 miRNAs have predicted targets involved in cell proliferation, apoptosis, stress response, PIK3/AKT/mTOR and TGF-β signaling pathways. Conclusion: Differentially expressed urinary exo-miRs may be useful markers to monitor tacrolimus therapy and graft function in kidney transplantation.
Keyphrases
- kidney transplantation
- cell proliferation
- poor prognosis
- signaling pathway
- binding protein
- end stage renal disease
- long non coding rna
- ejection fraction
- newly diagnosed
- cell cycle
- high resolution
- chronic kidney disease
- oxidative stress
- stem cells
- machine learning
- prognostic factors
- mass spectrometry
- epithelial mesenchymal transition
- induced apoptosis
- artificial intelligence
- cell therapy
- metabolic syndrome
- uric acid
- deep learning
- cell cycle arrest
- mesenchymal stem cells
- high density
- data analysis